Ethicon Opens Up To Chronic Sinusitis Market With $785 Mil. Acclarent Buy
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Ethicon will use its $785 million acquisition of Acclarent, developer of the Balloon Sinuplasty system for chronic sinusitis, as a platform for growth in the ear, nose and throat business